Mitochondrial Distress in Methylmalonic Acidemia: Novel Pathogenic Insights and Therapeutic Perspectives

Cells. 2022 Oct 10;11(19):3179. doi: 10.3390/cells11193179.

Abstract

Mitochondria are highly dynamic, double-membrane-enclosed organelles that sustain cellular metabolism and, hence, cellular, and organismal homeostasis. Dysregulation of the mitochondrial network might, therefore, confer a potentially devastating vulnerability to high-energy-requiring cell types, contributing to a broad variety of hereditary and acquired diseases, which include inborn errors of metabolism, cancer, neurodegeneration, and aging-associated adversities. In this Review, we highlight the biological functions of mitochondria-localized enzymes, from the perspective of understanding the pathophysiology of the inherited disorders destroying mitochondrial homeostasis and cellular metabolism. Using methylmalonic acidemia (MMA) as a paradigm of mitochondrial dysfunction, we discuss how mitochondrial-directed signaling pathways sustain the physiological homeostasis of specialized cell types and how these may be disturbed in disease conditions. This Review also provides a critical analysis of molecular underpinnings, through which defects in the autophagy-mediated quality control and surveillance systems contribute to cellular dysfunction, and indicates potential therapeutic strategies for affected tissues. These insights might, ultimately, advance the discovery and development of new therapeutics, not only for methylmalonic acidemia but also for other currently intractable mitochondrial diseases, thus transforming our ability to modulate health and homeostasis.

Keywords: epithelial cell distress; kidney tubule; metabolism; mitochondria; mitophagy; oxidative stress; signaling.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acid Metabolism, Inborn Errors* / therapy
  • Homeostasis
  • Humans
  • Mitochondria / metabolism
  • Mitochondrial Diseases* / metabolism

Supplementary concepts

  • Methylmalonic acidemia

Grants and funding

A.L. is supported by Cystinosis Research Foundation (Grant No. CRFS-2020-005 Irvine, CA, USA) and received financial support from the University Research Priority Program of the University of Zurich (URPP) ITINERARE-Innovative Therapies in Rare Diseases (Junior Grant). The funders had no role in the study design, data collection, and interpretation or in the decision to submit the work for publication.